Beqvez (previously Durveqtix): New gene therapy treatment for haemophilia B received approval from the European Commission
Year: 2024
Type: other
Abstract: After a positive draft opinion by the Committee for Advanced Therapies (CAT) on 24 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on Beqvez (previously Durveqtix) the 30 May. Following the CHMP opinion, the 24 July 2024, the European Commission granted a conditional marketing authorisation to this new treatment for adults with severe or moderately severe haemophilia B. More information on this newly authorised medicines on the EMA Website.
Source: OpenEdition (OpenEdition)
DOI: 10.58079/12ksg
Author: Vroby
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6936551578
Cites:
Cited by:
Related to: